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Abstract
Evidence is emerging that the closely related ROCK1 and ROCK2 serine/threonine kinases
support the invasive and metastatic growth of a spectrum of human cancer types. Therefore,
inhibitors of ROCK are under preclinical development. However, a key step in their development
involves the identification of genetic biomarkers that will predict ROCK inhibitor anti-tumor
activity. One identified mechanism for ROCK activation in cancer involves the loss of function of
the DLC1 tumor suppressor gene, which encodes a GTPase activating protein (RhoGAP) for the
RhoA and RhoC small GTPases. DLC-1 loss may lead to hyperactivation of RhoA/C and its
downstream effectors, the ROCK kinases. We therefore determined whether loss of DLC-1
protein expression identifies non-small cell lung carcinoma (NSCLC) cell lines whose growth and
invasion phenotypes are sensitive to ROCK inhibition. We identified and characterized a novel
small molecule pharmacologic inhibitor of ROCK and additionally applied genetic approaches to
impair ROCK1 and/or ROCK2 activity, and we determined that although NSCLC anchorage-
dependent growth was ROCK-independent, both anchorage-independent growth and Matrigel
invasion were ROCK-dependent. However, loss of DLC-1 expression did not correlate with
ROCK activation or with OXA-06 sensitivity. Unexpectedly, suppression of ROCK1 or ROCK2
expression alone was sufficient to impair anchorage-independent growth, supporting their non-
overlapping roles in oncogenesis. Mechanistically, the block in anchorage-independent growth
was associated with accumulation of cells in the G0/G1 phase of the cell cycle, but not increased
anoikis. We conclude that ROCK may be a useful therapeutic target for NSCLC.
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There is considerable and growing evidence for the importance of the ROCK serine/
threonine kinases (ROCK1/ROKβ and ROCK2/ROKα) kinases in oncogenesis (1,2). The
highly related ROCK1 and ROCK2 kinases function as key downstream effectors of the
RhoA small GTPase (3). ROCK regulates diverse cellular processes such as actomyosin
contractility, focal adhesion assembly, cytokinesis, and cell proliferation. ROCK has also
been implicated in colorectal, breast, gastric, and glioblastoma proliferation or anchorage-
independent growth (4–7) and in prostate, bladder, fibrosarcoma, melanoma, and
hepatocellular cancer metastatic growth (8–13). An evaluation of ROCK as a therapeutic
target for lung cancer has not been done.
Although preclinical development of ROCK inhibitors is ongoing, a number of issues need
to be resolved to facilitate their clinical development. First, genetic or biochemical
determinants that identify cancers responsive to ROCK inhibitors need to be identified.
Second, biomarkers that correlate with inhibitor anti-tumor response are needed for effective
clinical evaluation. Although the phosphorylation status of key substrates of ROCK is
widely utilized, their value as biomarkers for ROCK inhibition remains unresolved. Third,
the majority of studies implicating ROCK in cancer growth utilized the Y-27632 ROCK
inhibitor (1,2). Since Y-27632 can inhibit other protein kinases in vitro, whether the anti-
tumor activities ascribed to this inhibitor are target-based is unresolved.
One candidate molecular determinant for ROCK inhibitor sensitivity is the loss of
expression of the DLC1 tumor suppressor (14). DLC1 mRNA expression was lost in 95% of
NSCLC patient tumors and 58% of NSCLC cell lines (15,16). Due at least in part through its
function as a Rho GTPase activating protein and thus negative regulator of RhoA and the
related RhoB and RhoC, restoration of DLC-1 expression in DLC1 deficient NSCLC lines
resulted in reduction of cell migration, proliferation, anchorage-independent growth, in vitro
invasion, and tumorigenicity in nude mice (16–18), supporting its role as a tumor suppressor
(19). It is well-established that aberrant RhoA and RhoC activation can promote
tumorigenic, invasive and metastatic growth (20–22). Thus, by analogy to the loss of the
neurofibromin RasGAP or the tuberous sclerosis RhebGAP in cancer (23,24), loss of DLC-1
results in hyperactivation and persistent RhoA/C effector signaling (15,25). However, like
Ras, Rho GTPases are not tractable molecules for drug discovery (14). Instead, in further
analogy to Ras, where inhibitors of the Raf-MEK-ERK effector protein kinase pathway are
being considered for anti-Ras drug development (26), inhibitors of RhoA/C downstream
effector protein kinases, in particular ROCK, may also be attractive therapeutic targets for
DLC1-deficient NSCLC. In support of this possibility, ectopic expression of DLC-1
suppressed ROCK activation and ROCK-dependent motility in DLC-1 deficient
hepatocellular carcinoma cell lines (27)., and suppression of DLC-1 expression sensitized
liver cancer cells to reduced colony formation by pharmacologic inhibition of ROCK (19).
In light of the frequent loss of DLC1 expression in NSCLC, we speculated that DLC1 loss-
induced activation of RhoA/C will in turn cause ROCK activation-driven NSCLC
tumorigenic and malignant growth. However, previous studies implicating ROCK in cancer
growth have relied primarily on the use of Y-27632 ATP competitive ROCK1/2 kinase
inhibitor, which has additional off-target inhibitory activity for other kinases such as PKN
and MSK1 (28). To offset this concern, we utilized a structurally distinct and more potent
and selective small molecule ROCK1/2 inhibitor together with RNA interference depletion
of ROCK1/2 expression to validate a role for ROCK in DLC1 deficient NSCLC growth. We
determined that NSCLC anchorage-dependent growth was ROCK-independent, but
anchorage-independent growth and Matrigel invasion were ROCK-dependent. However,
loss of DLC-1 expression did not correlate with ROCK dependence. ROCK inhibition of
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growth was associated with inhibition of cell cycle progression rather than enhancement of
cell death. Our studies provide validation of ROCK for NSCLC therapy.
Materials and Methods
Identification and characterization of the OXA-06 ROCK inhibitor
ROCK1/2 cDNA sequences were subcloned into a baculovirus expression vector for protein
expression as a C-terminal fusion protein with His6 in insect cells. The expressed protein
(comprising residues 2–238 of ROCK1 fused to residues 255–548 of ROCK2) was purified
and used in a fluorescence polarization assay-based high-throughput screening campaign to
identify ROCK kinase inhibitors within OSI Pharmaceuticals compound library. The
screening assay buffer consisted of 10 mM Tris HCl (pH 7.2), 10 mM MgCl2, 0.1% BSA, 1
mM DTT and contained 100 nM substrate peptide (5′-FAM-AKRRRLSSLRA-COOH), 1
μM ATP and 12.5 nM ROCK kinase domain. A series of azaindole-based compounds was
selected for medicinal chemistry optimization, and synthetic routes for this series are
described within patent application WO2007084667. To determine the IC50 values of
OXA-06 and Y-27632 against ROCK, we utilized the above fluorescence polarization assay
with 12.5 nM ROCK fusion protein and 1.4 μM ATP (roughly the measured Km value) as
well as at 100 μM ATP. The IC50 for OXA-06 was measured 18 times, with the average and
standard deviation reported, and Y-27632 was measured three times, with the average and
standard deviation reported.
Protein kinase selectivity assays
Kinase selectivity assays were performed using ProfilerPro Kinase Selectivity Kits (Caliper
Life Sciences, Inc.) according to the manufacturer’s instructions. The extent of inhibition by
each compound is measured directly by quantifying the level of both unphosphorylated and
phosphorylated peptide substrate after electrophoretic separation. Assays were performed at
room temperature following a one h pre-incubation of compounds with the enzymes. Each
assay was performed on two separate occasions.
Quantitative assays of MYPT1 phosphorylation and cell migration in PANC-1 cells
Analysis of MYPT1 phosphorylation in PANC-1 cells by quantitative ELISA was
performed as described previously (29). PANC-1 cell migration was quantitated using 96-
well modified Boyden chamber migration assay plates (Chemicon, Temecula, CA). Cells
were applied to the upper chamber in growth medium supplemented with 0.5% fetal calf
serum (FCS), either in the presence or absence of inhibitor, and the cells were allowed to
migrate towards growth medium supplemented with 10% FCS for 16 h. The number of
migrated cells was then quantitated by labeling with Cyquant GRR (Invitrogen).
Cell Culture
NSCLC lines were obtained directly from the ATCC (Rockville, MD) and grown in
RPMI-1640 supplemented with 10% FBS.
Soft agar colony formation, Matrigel invasion, and anoikis assays
Anchorage-independent growth soft agar assays were done as previously described (30). For
inhibitor treatments, vehicle (dimethyl sulfoxide; DMSO) or OXA-06 was also added to the
medium at the final indicated concentrations. For siRNA treatments, cells were suspended in
soft agar 48 h post-transfection and maintained at 37 °C for 14–30 days, when viable
colonies were stained with the MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide) viability stain. The total number per plate of viable colonies >10 cells
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were quantified by counting the number of colonies in five representative fields of view
within each plate. Results are expressed as mean ± SD.
Invasion assays were performed with Growth Factor Reduced Matrigel Invasion Chambers
(BD Biosciences, San Jose, CA) according to the manufacturer’s protocol. For inhibitor
treatments, vehicle or OXA-06 were also added to the upper chamber. RPMI-1640
containing 3% FBS as a chemoattractant was added to the bottom well. Cells were allowed
to invade for 22 h at 37 °C and then non-invaders were removed. Invading cells were fixed
and stained with the Diff-Quik Stain Set (Dade Behring Inc., Newark, DE). Five fields were
counted for each chamber, and the total number of cells counted per chamber was used for
calculating the average number of invading cells. Results are expressed as mean ± SD.
For the MTT anchorage-dependent growth viability assay, 2 × 103 cells per well were
seeded in 96-well plates in octuplet. For ROCK inhibitor studies, growth medium
supplemented with vehicle or OXA-06 was also added to the wells. Cells were incubated for
two days for the siRNA and four days for inhibitor analyses. Optical density at 560 nm was
recorded and normalized to either vehicle control non-specific siRNA control. Values shown
are the mean ± SD.
For the anoikis assays, cells were plated on Ultra-Low Attachment plates (Corning, Lowell,
MA) with RPMI-1640 plus 10% FCS, and either vehicle, 10 μM OXA-06, or 10 μM
staurosporine (positive control for induction of apoptosis). Cells with staurosporine were
harvested and lysed after 6 h. All other cells were harvested and lysed after 48 h, and then
immunoblotted for PARP and caspase-3 as described below in western blot analyses section.
Flow cytometry cell cycle analysis
NSCLC cells were plated on Ultra-Low Attachment Plates (Corning) with RPMI-1640
supplemented with 10% FCS, and either vehicle or 10 μM OXA-06 for 48 h. After
treatment, cells were collected, washed twice with phosphate-buffered saline (PBS) and
fixed in 70% ethanol overnight. After centrifugation, cells were stained with a buffer
containing 20 μg/ml propidium iodide (Roche, Indianapolis, IN) and 200 μg/ml RNAse A
(Qiagen) in PBS. Analyses were performed on a CyAn flow cytometer (Beckman-Coulter,
Brea, CA). Cell cycle distribution was determined using FlowJo (TreeStar, Inc., Ashland,
OR). Experiments were performed two independent times and values are shown as means ±
S.D.
Statistical analysis
Data were analyzed using an unpaired t test. Values are shown as means ± S.D. A P value
<0.01 was considered significant.
Western blot analyses
For OXA-06 treatment immunoblots, cells were treated with 1 h with vehicle or the
indicated OXA-06 concentration as this treatment time was previously shown to be
sufficient for maximal ROCK inhibition effect (29). The following antibodies were then
used for immunoblot analysis: pMYPT1(T853) (US Biologicals, Marblehead, MA), MYPT1
(Covance, Princeton, NJ), pCofilin (Ser3) and Cofilin (Cell Signaling Technology, Danvers,
MA), β-actin (Sigma-Aldrich, St. Louis, MO). Pull down analyses to determine steady-state
levels of RhoA-GTP were done as we have described previously using a glutathione S-
transferase fusion protein containing the RhoA-GTP binding domain of Rhotekin and anti-
RhoA antibody (Cell Signaling Technology) (31). For anoikis immunoblot analyses,
suspension cell cultures were treated with staurosporine (Calbiochem, San Diego, CA) for 6
h, or with vehicle or OXA-06 for 48 h. The following antibodies were then used to detect the
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indicated proteins: PARP (Cell Signaling Technology), caspase-3 (Cell Signaling
Technology), and vinculin (Sigma-Aldrich). For cell cycle immunoblot analyses, suspension
cells were treated with vehicle or 2 or 10 μM OXA-06 for 48 h. The following antibodies
were used to detect: phosphorylated (Ser608) Rb (Cell Signaling Technology), total Rb
(Santa Cruz Biotechnology, Santa Cruz, CA), and β-actin. For the siRNA immunoblot
analyses, immunoblot analysis of ROCK1, ROCK2, phospho-MYPT1(T853), MYPT1,
phospho-cofilin (Ser3), cofilin, and β-actin was done.
siRNA suppression of ROCK1 and ROCK2 expression
siRNA oligonucleotides (Stealth siRNA, as we described previously (29) were diluted to 20
μM in nuclease-free water and the transfection was performed with Lipofectamine2000
(Invitrogen) according to manufacturer’s protocols and as described previously (29).
Forty-eight h after transfection, transfected cells were harvested for either analyses of
anchorage-independent growth or for western blot analyses. Data were analyzed using a
paired t test. Values are shown as means ± S.D. A P value <0.01 was considered highly
significant.
Results
OXA-06 is a novel and potent ROCK inhibitor
In light of the off-target activities of the Y-27632 ROCK inhibitor, we initiated a high-
throughput screening of the OSI Pharmaceuticals compound library using recombinant
chimeric ROCK1/2. A series of compounds was identified for medicinal chemistry
optimization, resulting in the identification of a potent ATP-competitive ROCK inhibitor,
designated OXA-06, that is structurally distinct from the widely used Y-27632 ROCK1/2
inhibitor (Fig. 1). We first compared the in vitro potency of OXA-06 with Y-27632 for
ROCK in vitro. OXA-06 exhibited an IC50 value of 0.01 ± 0.005 μM, while Y-27632
measured 0.24 ± 0.09 μM when measured with an ATP concentration of 1.4 μM, making
OXA-06 roughly 25-fold times more potent in vitro. When performed at 100 μM ATP
concentrations, IC50 values of OXA-06 were similarly about 25-fold more potent than
Y-27632. To evaluate selectivity, we chose 200 nM for OXA-06 and 10 μM for Y-27632,
concentrations at which roughly 95% of ROCK1 and ROCK2 are inhibited by each
respective compound. We performed kinase selectivity assays using the ProfilerPro Kinase
Selectivity Kits comprised of 216 pharmacologically relevant wild type or mutant protein
kinases. Consistent data were generated for 183 kinases within this analysis (assays that
failed in one or more assay, or which did not generate data with CV values below 25% are
not included) (Supplementary Table 1). Clear selectivity differences were noted between the
two compounds. OXA-06 showed >50% inhibition of 9 out of 167 (5.4%) whereas Y-27632
inhibited 17 out of 167 (10.2%) (Fig. 1B). Both shared activity for five additional protein
kinases, whereas OXA-06 was active on two other kinases and Y-27632 was active on 10
additional kinases. These results demonstrate the greater selectivity of OXA-06 over
Y-27632. Additionally, this degree of selectivity is comparable or better than highly
selective protein kinase inhibitors (e.g., imatinib, gefitinib) currently in clinical use (32,33).
We conclude that the different and improved kinase inhibition selectivity profile, together
with being structurally distinct from Y-27632, support the usefulness of OXA-06 to
investigate the role of ROCK kinase activity in cellular processes.
We next determined if OXA-06 could block ROCK activity in intact cells. We determined
previously that siRNA suppression of ROCK1 and ROCK2 expression, and additionally
treatment with three different ROCK1/2 inhibitors, reduced the phosphorylation of MYPT1
at T853 was ROCK-dependent in PANC-1 pancreatic tumor cells (29). PANC-1 migration
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was also shown previously to be ROCK-dependent (34). We determined that OXA-06
treatment of PANC-1 cells showed dose-dependent inhibition of MYPT1 phosphorylation
(IC50 300 nM) and migration in vitro (Supplementary Fig. 1). By comparison Y-23732
showed a reduced potency to inhibit MYPT1 phosphorylation (IC50 1.4 μM) and migration.
OXA-06 blocks anchorage-independent growth and invasion of NSCLC lines
We next utilized OXA-06 to validate the importance of ROCK1/2 as therapeutic targets.
Western blot analyses of 16 NSCLC cell lines determined that all lines express ROCK1 and
ROCK2 protein (Fig. 2A). Based on previous studies with other cancer types (19,27), we
hypothesized that the absence of DLC-1 expression might be a predictor of sensitivity to
inhibition of ROCK1 and/or ROCK2. For these analyses, we evaluated the A549, H23 and
H358 cell lines which lack DLC-1 protein expression, and the H1299 and H1703 cell lines
that express high levels of DLC-1 (18).
Surprisingly, none of the cell lines was inhibited in anchorage-dependent proliferation by
treatment with 2 or 10 μM OXA-06 (Fig. 2B). However, at the highest concentration of
OXA-06 used, 10 μM, greater than 90% anchorage-independent growth inhibition was
achieved in all the lines tested (Fig. 2C). While 400 nM was sufficient to cause ~90%
reduction in the colony formation activity of the DLC-1 positive H1299 cell line, this
concentration did not cause statistically significant inhibition of the DLC-1 negative A549
and H358 or the DLC-1 positive H1703 cell lines.
Since OXA-06 also inhibited seven other kinases in vitro (e.g., PKA), we also assessed the
ability of Y-27632 to inhibit anchorage-independent growth of H1299 and A549 cells. In
both lines, Y-27632 also caused a decrease in anchorage-independent growth, suggesting a
ROCK-dependent for anchorage-independent growth, although Y-27632 had much weaker
potency than OXA-06 (Fig. 3). This increased potency of OXA-06 compared to Y-27632 in
blocking anchorage-independent growth is consistent with its increased potency in vitro and
in ROCK-dependent cell-based assays (Fig. 1B, Supplementary Table 1 and Supplementary
Fig. 1). Similar to their sensitivity to inhibition of anchorage-independent growth by
OXA-06, both DLC-1 negative and positive NSCLC cell lines showed comparable dose-
dependent sensitivities to OXA-06 suppression of Matrigel invasion, with ~70% inhibition
seen at 2 μM (Fig. 2D). The observation that Matrigel invasion and anchorage-independent
growth were inhibited at similar concentrations of OXA-06 is consistent with the inhibitor
blocking both tumor phenotypes through inhibition of the same target(s). We conclude that
loss of DLC-1 did not correlate with increased sensitivity to OXA-06.
One possible basis for the lack of correlation between DLC-1 loss of expression and
increased sensitivity to OXA-06 is that DLC-1 expression alone does not determine the
steady-state level of RhoA activation. The activities of RhoGEFs as well as RhoGAPs will
also influence RhoA steady-state levels. Consistent with this possibility, we performed pull
down analyses to quantitate the steady-state levels of active RhoA-GTP in a panel of
NSCLC cell lines. We found no direct correlation between elevated RhoA-GTP levels the
absence of DLC-1 protein expression (Fig. 2E).
OXA-06 anti-tumor activity correlates with suppression of Cofilin phosphorylation
To investigate the mechanism of OXA-06-mediated inhibition of growth and invasion, we
determined if the anti-tumor activity of OXA-06 correlated with inhibition of ROCK
activity. Two well-characterized ROCK-dependent phosphorylation activities are direct
ROCK phosphorylation of the MYPT1 and the indirect phosphorylation of Cofilin through
ROCK phosphorylation and activation of LIMK1/2. However, since both MPYT1 and
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Cofilin can be phosphorylated by ROCK-independent mechanisms, their phosphorylation
state may or may not accurately monitor ROCK activity.
We found that OXA-06 treatment reduced pMYPT1 and pCofilin levels at concentrations
that coincided with that required to block anchorage-independent growth. These data are
consistent with ROCK inactivation as a key mechanism for OXA-06 anti-tumor activity.
However, the extent of phosphorylation reduction and the inhibitor concentration required
for this effect varied between different cell lines (Fig. 4). Generally, we found that pCofilin
provided the most accurate marker for OXA-06 growth inhibition activity for all five
NSCLC cell lines evaluated. For example, H1299 cells were the most sensitive to OXA-06
colony suppression (Fig. 2C) and pCofilin reduction was seen at the lowest concentrated
used, 80 nM. In contrast, H358 cells were the most resistant to OXA-06 colony suppression
and even at the highest concentration studied (10 μM), incomplete reduction in pCofilin was
seen. For the remaining three NSCLC cell lines, 10 μM was required for near-complete
suppression of pCofilin as well as soft agar growth. In contrast, pMYPT1 levels were less
informative, largely because two cell lines lacked detectable phosphorylation in untreated
cells. For A549, but not H358 cells, this was most likely due to the barely detectable levels
of MYPT1 expression. Where it could be detected, pMYPT1 did show dose-dependent
reduction that coincided with OXA-06 concentrations needed for growth inhibition. Thus,
Cofilin phosphorylation may provide a useful biomarker for ROCK inhibition in NSCLC.
Genetic suppression of ROCK1 and/or ROCK2 expression phenocopies the biochemical
and biological activities of OXA-06
Although ROCK1/2 were the protein kinases most potently inhibited by OXA-06 in vitro
(Table 1), it is possible that the effects of OXA-06 on NSCLC anchorage-independent
growth and invasion resulted from inhibition of other kinases. To confirm that ROCK kinase
inhibition contributes to the anti-tumor activity of OXA-06, we specifically reduced ROCK1
and ROCK2 expression with siRNA validated previously to be selective inhibitors of
ROCK1 and ROCK2 (29). We utilized two independent siRNA sequences each for ROCK1
and ROCK2 in H1299 cells that caused near complete knockdown of ROCK1 and/or
ROCK2 protein expression (Fig. 5A). Interestingly, neither ROCK1 nor ROCK2 depletion
individually was able to strongly reduce pMYPT1 or pCofilin, and instead, concurrent
depletion of both was required to reduce pMYPT1 and to a lesser extent pCofilin (Fig. 5A).
This result demonstrates that both ROCK isoforms are functionally redundant for these
signaling activities.
In contrast, we found that depletion of either ROCK1 or ROCK2 alone, using two
independent siRNA sequences each, was sufficient to potently (~90%) inhibit the
anchorage-independent growth of H1299 cells. Concurrent suppression of both ROCK1 and
ROCK2 more effectively suppressed growth with a near complete suppression of colony
formation (Fig. 5B). Thus ROCK1 and ROCK2 each contribute non-redundant activities to
support anchorage-independent growth. Finally, we determined that, similar to OXA-06
treatment, concurrent depletion of ROCK1 and ROCK2 did not significantly impair
anchorage-dependent proliferation (Fig. 5C). That siRNA for ROCK1 and ROCK2
phenocopied the biological activities of OXA-06 suggests that the anti-tumor activities seen
with OXA-06, despite having other protein kinase targets, are likely due primarily to
inhibition of ROCK1 and ROCK2.
OXA-06 stimulates accumulation in G0/G1 phase but not apoptosis in nonadherent NSCLC
cells
Although we found that prolonged OXA-06 treatment did not reduce NSCLC cell line
viability on plastic (Fig. 3B), this result did not exclude the possibility that OXA-06
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rendered NSCLC cells more sensitive to suspension-induced apoptosis (anoikis). We
therefore investigated possible apoptotic effects of OXA-06 during blockade of anchorage-
independent growth of NSCLC cells. We saw no evidence for caspase-3 cleavage in A549
or H1299 cells, and only partial PARP cleavage in A549 but not H1299 cells in suspension
cells, even when treated with the high concentration of 10 μM OXA-06, while the positive
control of 10 μM staurosporine demonstrated clear PARP and caspase-3 cleavage
(Supplementary Fig. 2A). Thus increased anoikis sensitivity is not a mechanism for the
decreased anchorage-independent growth seen with OXA-06.
We next determined if OXA-06 impaired soft agar colony formation by disruption of cell
cycle progression under anchorage-independent conditions. We used propidium iodide
staining and flow cytometry to investigate possible cell cycle distribution effects of OXA-06
on two NSCLC cell lines treated with inhibitor in suspension. OXA-06 treatment at 1 μM in
suspension (a concentration that is around the cellular IC50 value for reduced anchorage-
independent growth, invasion, and downstream ROCK target phosphorylation) caused a
statistically significant reduction in S phase and an increase in G0/G1 (Fig. 6A).
To confirm that ROCK inhibition is required for these effects of OXA-06, we used siRNA
to reduce ROCK1 and ROCK2 protein expression and we found that concurrent suppression
of ROCK1 and ROCK2 expression also caused a very similar cell cycle phenotype (Fig.
6B). This result suggests that these activities of OXA-06 on the cell cycle are due to
inhibition of ROCK. Furthermore, we did not detect any sub-G0 peaks in the analysis of
OXA-06 at 1 μM (Fig. 6) or at 10 μM (data not shown), or ROCK1/ROCK2 siRNA (Fig. 6),
which when taken together with lack of full caspase-3 or PARP cleavage, excludes anoikis
or necrosis as a mechanism for the ROCK inhibition-dependent block in anchorage-
independent growth.
Finally, we evaluated the effects of OXA-06 treatment on two key regulators of G1
progression, the Rb tumor suppressor and cyclin D1. Using western blot analysis on
OXA-06 treated A549 or H1299 cells in suspension at 2 or 10 μM, we did not observe
increased Rb phosphorylation at S608 (a site phosphorylated by cyclin/CDK complexes) nor
decreased levels of cyclin D1 (Supplementary Fig. 2B). We also did analysis for two
regulators of Rb phosphorylation, p21/CIP1 and p27/KIP1 and we found no consistent and
significant changes in their levels of expression upon OXA-06 treatment (data not shown).
These results indicate that OXA-06 blocks anchorage-independent growth by causing cell
cycle arrest in G0/G1 through a mechanism involving other regulators of G1 progression.
Discussion
In light of their role as key effectors of the RhoA and RhoC small GTPases which have
validated roles in oncogenesis (20,21), ROCK1/2 are being considered as therapeutic targets
for cancer (1,2). The first goal of our study was to rigorously validate ROCK as a useful
therapeutic target for NSCLC. The majority of previous studies with this goal utilized
Y-27632 or its close structural relatives Wf-536 or fasudil, which are known to also potently
block the activities of other protein kinases (28). To overcome this limitation with Y-27632,
we utilized a second novel ROCK inhibitor. OXA-06 exhibited increased potency to block
ROCK-dependent signaling in cell-based assays, and additionally exhibited less off-target
protein kinase inhibitory activities in vitro. Therefore, when used in conjunction with a
structurally distinct ROCK inhibitor with a distinct off-target activity profile, concurrently
with two independent siRNAs each targeting ROCK1 and/or ROCK2, we feel that our
analyses provide an accurate assessment of ROCK function in lung cancer growth.
Generally, RNAi depletion of a protein kinase, where there is a loss of entire protein
expression, may not accurately model pharmacologic inhibition of the catalytic activity
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alone, where a kinase-inactive protein persists and may retain non-kinase functions.
However, our finding that RNAi depletion and pharmacologic inhibition of ROCK exhibited
essentially identical consequences on NSCLC growth suggests that the anchorage-
independent growth and Matrigel invasion inhibition seen is due to loss of ROCK protein
kinase function. Furthermore, as discussed below, our findings that OXA-06 anti-tumor
activity correlated well with OXA-06 inhibition of phosphorylation of known direct and
indirect ROCK substrates and that siRNA for ROCK phenocopied the effects of OXA-06 on
anchorage-dependent and -independent growth strongly support our conclusion that ROCK
kinases represent functionally relevant targets of OXA-06 in NSCLC growth. Thus, while
OXA-06 can inhibit other protein kinases, our siRNA results argue that the anti-tumor
activity observed in NSCLC cell lines may be due primarily to ROCK inhibition. The FDA
approval of the dasatinib and sunitinib protein inhibitors for cancer treatment, both of which
show activity (Kd <100 nM) for greater than 15% of the 290 protein kinases tested (38),
clearly demonstrate that multi-kinase inhibitors can be developed successfully for
therapeutic use. OXA-06 does not have sufficient pharmacokinetic/pharmacodynamic
properties for use in animal studies (unpublished observations), but it provides a more potent
and selective inhibitor than the widely used Y-27632 compound to study ROCK function in
cell culture. More importantly, our results support the discovery and development of potent
and selective ROCK inhibitors in animal models of NSCLC.
The second goal of our study was to determine if DLC-1 loss of expression is a reliable
biomarker for NSCLC tumor cell ROCK dependency. In contrast to two recent studies that
found ROCK important for DLC-1 tumor suppressive effects in hepatocellular carcinoma
(19,27), we found that DLC-1 expressing and deficient cells were comparably sensitive to
OXA-06 and additionally showed comparable levels of phosphorylation of ROCK
substrates. This disconnect is not entirely surprising for several reasons. First, there exist a
multitude of GEFs and GAPs for RhoA/C (14). Thus, the steady-state activation of RhoA-C
and ROCK may not be dictated solely by loss of DLC-1 alone. Consistent with this
possibility, we found no direct correlation between the level of DLC-1 protein reduction and
increased cellular RhoA-GTP levels. Furthermore, in studies of a DLC-1 mutant that failed
to associate with focal adhesions, this disrupted subcellular localization was not associated
with a loss in the ability to lower total cellular RhoA-GTP levels (39). Thus, it is not
surprising that total RhoA-GTP levels are not tightly linked to the level of DLC-1
expression. Second, RhoA/C may utilize non-ROCK effectors to promote tumorigenesis
(37). Finally, DLC-1 can also serve as a GAP for other Rho family proteins and DLC-1
tumor suppressor function involves both Rho-dependent and Rho-independent mechanisms
(18). These additional complexities of DLC-1 function may prevent a simple and direct
relationship between DLC-1 expression loss and ROCK-dependent growth. Perhaps the
combined use of DLC-1 loss together with hyperphosphorylation of ROCK substrates will
provide a more reliable marker to predict ROCK dependency.
The third goal of our study was to determine if the widely studied substrates for ROCK
activity provided accurate biochemical markers that correlated with OXA-06-mediated
growth inhibition. While our studies found that Cofilin, rather than MYPT1, provided a
more accurate biomarker for pan-ROCK inhibitor treatment, our use of isoform-specific
siRNA to selectively silence ROCK1 or ROCK2 found that inhibition of either isoform
alone inhibited anchorage-independent growth, yet inhibition of both ROCK1 and ROCK2
were required to suppress Cofilin phosphorylation. Thus, ROCK1 and ROCK2 may be
functionally overlapping for Cofilin phosphorylation but serve non-overlapping roles in
NSCLC growth, although whether they are truly functionally distinct remains to be
rigorously evaluated. These results support the value of investigation of isoform-specific
ROCK inhibitors, which may provide reduced off-target activities, and the need for
additional biomarkers for ROCK isoform-selective inhibitors. Nevertheless, our observation
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that combined inhibition of ROCK1 and ROCK2 has strong anti-cancer activity in NSCLC
lines supports the further development of ROCK dual-selective inhibitors for lung cancer.
One surprising observation was the failure of OXA-06 to impair anchorage-dependent
NSCLC tumor cell growth at a concentration (10 μM) that potently blocked soft agar colony
formation and Matrigel invasion. This activity begins to shed some light on the role of
ROCK in NSCLC tumor growth. When evaluated on cells in suspension, we found that
OXA-06 treatment did not increase apoptosis or necrosis and instead caused a G0/G1 arrest,
although it is possible that other less-well understood types of cell death in combination with
the cell-cycle arrest seen are responsible for the striking inhibition of anchorage-independent
growth seen with ROCK inhibition and knockdown. While our analyses did not establish a
mechanism for why ROCK dependency was not evident for cells grown on plastic, previous
studies suggest that loss of integrin-dependent signaling events (38,39) are a likely basis for
ROCK dependency for cells in suspension. Finally, how tumor cells will respond to ROCK
inhibition within the context of host stromal tissue will be an important future question to
address using both pharmacologic inhibitors and conditional ROCK knockouts in mouse
models of lung cancer.
In summary, our studies provide strong validation of ROCK1 and/or ROCK2 as useful
targets for NSCLC therapy. Furthermore, despite the potentially significant off-target
activities of our newly identified OXA-06 ROCK inhibitor, our demonstration that OXA-06
NSCLC anti-tumor activity correlates well with ROCK inhibition argues that, as with other
multi-kinase inhibitors FDA-approved for cancer treatment, a highly selective ROCK
inhibitor may not be essential for clinical success of ROCK inhibitors. Finally, our failure to
validate DLC-1 loss as a genetic marker for ROCK dependency or pCofillin as a biomarker
for ROCK inhibition defines these two areas where more progress will be needed if ROCK
inhibitors will be developed successfully.
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Figure 1. OXA-06 is structurally distinct from Y-27632 and is a more potent and selective
inhibitor of ROCK1 and ROCK2 in vitro
Structures of OXA-06 and Y-27632.
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Figure 2. OXA-06 treatment blocks anchorage-independent growth and invasion in NSCLC cell
lines, independent of DLC1 status
A, ROCK1 and ROCK2 proteins are expressed all NSCLC cell lines. The indicated NSCLC
cell lines were lysed and resolved by SDS-PAGE, and then blotted with ROCK isoform-
specific antibodies. B, Cell viability was measured using the MTT assay after treatment of
the indicated cell lines with vehicle (DMSO) or the indicated concentrations of OXA-06 for
4 d. Data shown are the O.D. values relative to vehicle and represent the mean ± SD of
octuplet wells and are representative of two independent experiments. C, Colony formation
of NSCLC cell lines in soft agar in growth medium supplemented with vehicle (DMSO) or
the indicated concentrations of OXA-06. The number of viable proliferating colonies were
stained by MTT and counted after 30 d, except for A549 and H1299 cells, which were
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counted after 14 d. Data shown are the percent colonies relative to vehicle, are the average ±
SD of triplicate wells, and are representative of at least two independent experiments. D,
Invasion of the indicated NSCLC cell lines was assayed by Matrigel transwell assays with
vehicle (DMSO) or the indicated concentrations of OXA-06 after 22 h. Data shown are the
percent invaded cells relative to vehicle, are the average ± SD of triplicate chambers and are
representative of at least two independent experiments. For panels B–D, DLC-1 protein
expression as determined by western blot analyses are indicated as detectable (DLC-1
positive) or undetectable (DLC-1 negative, as we determined previously. E, Elevated steady-
state RhoA activity levels do not correlate with loss of DLC-1 expression. Pull down
analyses, followed by blot analysis for RhoA, was done to measure the level of activated
RhoA-GTP and total RhoA expression. β-actin blot analysis was done to verify equivalent
total protein loading.
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Figure 3. OXA-06 exhibits greater potency than Y-27632 for inhibition of NSCLC anchorage-
independent growth
Colony formation of A549 (Panel A) or H1299 (Panel B) NSCLC cell lines in soft agar in
growth medium supplemented with vehicle (DMSO) or the indicated concentrations of
OXA-06 or Y-27632. The number of viable proliferating colonies were stained by MTT and
counted after 14 d. Data shown are the percent colonies relative to vehicle, are the average ±
SD of triplicate wells, and are representative of at least two independent experiments.
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Figure 4. OXA-06 treatment reduces steady-state levels of phospho-Cofilin and phospho-MYPT1
in NSCLC lines
DLC-1 negative or positive cell lines were treated with vehicle (DMSO) or the indicated
concentrations of OXA-06 for 1 h. Western blot analysis using phospho-specific antibodies
for pMYPT1 (pT853) and pCofilin (pS3) and for total MYPT1 and Cofilin.
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Figure 5. Concurrent suppression of ROCK1 and ROCK2 expression does not impair cell
viability, but is required to block downstream phosphorylation but not anchorage-independent
growth
H1299 NSCLC cells were transfected with non-specific (NS) siRNA or two different siRNA
sequences targeting ROCK1 or ROCK2. A, Concurrent suppression of ROCK1 and ROCK2
expression blocks phospho-MYPT1 and to a lesser degree phospho-Cofilin. After 48 h,
lysates were harvested and western blot analysis was performed using the indicated
antibodies. B, Suppression of ROCK1 or ROCK2 expression alone is sufficient to impair
anchorage-independent growth. Forty-eight h post-transfection, cells were suspended in soft
agar. The number of viable proliferating colonies were stained by MTT and counted after 14
d. Data shown are the percent colonies relative to vehicle, are the average ± SD of triplicate
wells and are representative of at least two independent experiments. C, Concurrent
suppression of ROCK1 and ROCK2 expression does not affect cell viability. Forty-eight h
post-transfection, cells were split at 5 × 103 cells/well and cell viability was measured MTT
assay analysis. Data shown are the O.D. values relative to non-specific siRNA and represent
the mean ± SD of octuplet wells and are representative of two independent experiments.
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Figure 6. OXA-06 and suppression of ROCK1/2 expression causes a block in G0/G1 in NSCLC
lines when in suspension
The indicated NSCLC cell lines were plated on Ultra-Low Attachment plates and incubated
with A, DMSO (Vehicle) or 1 μM OXA-06 for 48 h, or B, transfected with non-specific
(NS) siRNA or ROCK1 siRNA #1 and ROCK2 siRNA #1 sequences targeting ROCK1 or
ROCK2. Forty-eight h post-transfection, the cells were plated on Ultra-Low Attachment
plates (Corning). The cell-cycle dependent DNA content for the indicated treatments is
shown on the left (each representative of the three experiments), and the means and standard
deviations of cell-cycle percentages for the three independent experiments are shown on the
right.
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Table 1























Percent inhibition of a panel of protein kinases performed using ProfilerPro Kinase Selectivity Kits with 10 μM Y-27632 or 200 nM OXA-06. This
table shows all kinases inhibited by >50% (grey boxes) by either OXA-06 or Y-27632 compiles from Supplementary Table 1. Data shown are
representative of two independent experiments.
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